evipedia.ai
← Back

Thai Ginseng for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Kaempferia parviflora, Black Ginger, Thai Black Ginger, Krachai Dam, Krachaidum

Motivation

Thai ginseng is the dark purple underground stem of a plant from the cool uplands of Thailand, Laos and Myanmar. Despite the name it is not a ginseng but a close relative of common ginger, and Thai villagers know it as black ginger. It has drawn attention because a handful of unusual plant compounds in the root appear to act on blood vessels and on the way the body burns fuel.

For generations the root was sliced and steeped in rice liquor as a working man’s tonic for stamina, digestion and sexual vigor, which is how it earned its regional reputation as a plant-based alternative to prescription treatments for erectile difficulty. Over the past two decades Japanese and Korean food companies have turned it into measured capsules and marketed it for abdominal fat and exercise capacity, and it now turns up in sports blends and men’s health formulas worldwide.

This review examines what controlled human studies show about the root across body composition, physical performance and sexual function, how it is thought to work, what is known about its safety and its behavior alongside medicines, and how much weight the evidence can carry given who funded it.

Benefits - Risks - Protocol - Conclusion

Sources below give a high-level orientation to Thai ginseng: its chemistry, its two proposed mechanisms, and the commercial framing that surrounds it.

Only four items are listed rather than five. Beyond these, the available material is either promotional supplement-retailer writing, catalogue entries, or systematic reviews that belong in the section below; padding the list with marginal content would misrepresent how thin the accessible literature is. No relevant content on this plant exists on foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com or lifespan.io, and none of those platforms has covered it under any of its names.

Grokipedia

Kaempferia parviflora

Covers botany, traditional distribution, methoxyflavone chemistry and the commercial supplement trade in one place, which is useful for separating the plant itself from the branded extracts sold from it.

Examine

Thai Ginseng

Examine’s dedicated intervention page, last revised in August 2025, files the plant under men’s health and frames it as an herbal supplement used mainly to improve male sexual function.

ConsumerLab

No ConsumerLab article on Thai ginseng exists. The ingredient has never been included in a ConsumerLab product review or testing program, so no independent label-accuracy or purity data are available from that source.

Systematic Reviews

Three evidence syntheses cover this plant: two dedicated to it, and one large supplement network meta-analysis in which it appears as a comparator.

The central trade-off for this intervention is a small metabolic and performance benefit set against an unquantified drug-interaction risk. The benefit side is represented above; no systematic review or meta-analysis of the safety, toxicity or interaction literature exists, so that side of the trade-off is unrepresented in this section.

Mechanism of Action

Activity is attributed to methoxyflavones — flavonoid molecules carrying several methyl-oxygen groups — concentrated in the rhizome, chiefly 5,7-dimethoxyflavone, 5,7,4’-trimethoxyflavone and 3,5,7,3’,4’-pentamethoxyflavone.

Three pathways are proposed. Vascular: the extract raises output of nitric oxide (a gas that signals blood vessels to widen) from the cells lining vessels, and its methoxyflavones weakly inhibit PDE5 (phosphodiesterase-5, the enzyme that terminates that widening signal, and the target of sildenafil). Metabolic: the same compounds activate AMPK (an enzyme that switches cells from storing fuel to burning it), bind PPAR-γ (a master switch controlling fat-cell formation), and acutely raise whole-body energy expenditure in people with active brown adipose tissue (heat-generating fat). Cellular: one methoxyflavone binds and activates SIRT1 (a protein governing cellular stress and repair responses) more strongly than resveratrol does.

Pharmacologically the measured markers are short-lived, with a blood half-life of 2–3 hours in humans, non-selective across those targets, distributed highest to liver and kidney with smaller amounts reaching lung, testis and brain in rats, and cleared by demethylation followed by sulfation and glucuronidation. They both inhibit and are handled by CYP3A4 (cytochrome P450 3A4, the enzyme family that metabolizes most prescription drugs).

A competing reading holds that little of this operates systemically: oral bioavailability is 1–4% in rats, and peak human blood levels sit far below the concentrations at which enzyme inhibition and SIRT1 activation are measured in the test tube, leaving gut-level action or unidentified metabolites as the alternative explanations.

Historical Context & Evolution

Krachai dam was not developed as a medicine. Rhizomes were sliced into rice liquor and left to macerate for weeks, and the resulting tonic was drunk in northern Thailand and Laos for stamina during field work, for digestive complaints, gout and allergy, and as an aphrodisiac for older men. Village practice also applied it topically for muscle pain.

Its move into health optimization came in two waves. From 2004 to 2012 Thai pharmacology groups isolated the methoxyflavones and showed concretely what the folk claims might rest on: the compounds relaxed isolated rat aorta, raised nitric oxide release from human endothelial cells, and inhibited PDE5. The measured potency was several orders of magnitude weaker than sildenafil, a figure that cut both ways — it explained the traditional use and simultaneously set a ceiling on it.

The second wave was commercial and Japanese. After rodent work showed reduced fat accumulation and higher energy expenditure, food companies reframed the rhizome as a metabolic ingredient, funded the human abdominal-fat trials, and branded standardized extracts.

The 2017 clinical synthesis did not overturn the sexual-function claims so much as expose how thin the human record was: seven small trials, positive but fragile signals, no adverse events. Nothing published since has retired that hypothesis. The research money simply moved to body composition, where a regulated health-claim pathway exists in Japan and Korea and a return on trial spending can be recovered.

Expected Benefits

High 🟩 🟩 🟩

Reduction in Visceral and Total Body Fat

The most replicated human finding. Three 12-week randomized, double-blind, placebo-controlled trials in overweight Japanese and Korean adults each reported significantly greater loss of abdominal and whole-body fat than placebo, measured by scan rather than scale. The proposed mechanism is brown adipose tissue activation plus suppressed fat-cell formation, supported by a human study where a single dose raised energy expenditure only in people with active brown fat. Every trial was run or funded by an extract manufacturer — Maruzen Pharmaceuticals, Tokiwa Phytochemical, Daehan Chemtech — and none has been independently replicated.

Magnitude: Over 12 weeks at 150 mg daily, visceral fat area fell 3.67 cm² against a 0.50 cm² gain on placebo, and total abdominal fat fell 11.46 cm² against a 4.71 cm² gain (Yoshino et al., 2018); a 2025 trial in 83 Korean adults found significantly greater loss of body fat mass, body weight and visceral fat area than placebo (Sung et al., 2025).

Improved Muscular Strength and Exercise Capacity ⚠️ Conflicted

Two meta-analyses and three controlled trials point one way. In adolescent athletes, 360 mg daily for 12 weeks raised grip strength, back-and-leg strength and maximal oxygen uptake and cut 50-meter sprint time; a functional drink at 90–180 mg raised oxygen uptake and shuttle-run performance; 90 mg daily improved chair-stand and six-minute-walk performance in older volunteers. Against this, a single-dose trial found no sprint or endurance effect. Effect sizes are small, and the athlete trials came from one Thai university group.

Magnitude: Standardized mean difference 0.46 for muscular strength versus placebo in a network meta-analysis of 80 supplement trials (Luo et al., 2025) — the only agent of 31 tested to reach significance on that endpoint; the underlying soccer-player trial used 180 mg daily for 12 weeks (Promthep et al., 2015).

Medium 🟩 🟩

Lower Fasting Blood Glucose ⚠️ Conflicted

Pooled human data show a modest fall in fasting glucose, consistent with PPAR-γ binding and AMPK activation. The one trial designed to test glucose handling directly contradicts it: an oral glucose tolerance test in healthy volunteers given 90 or 180 mg daily for 28 days found no effect. The plausible reconciliation is that benefit is confined to people with elevated baseline glucose or excess visceral fat and absent in metabolically healthy volunteers — but that has never been tested directly.

Magnitude: Standardized mean difference -0.51 (95% confidence interval -0.98 to -0.05) for fasting blood glucose across human studies (Na Takuathung et al., 2024); against this, no change in glucose tolerance at 90 or 180 mg daily for 28 days (Sripanidkulchai et al., 2019).

Improved Erectile Function and Sexual Satisfaction

The traditional use, and the one with a plausible enzyme target: the methoxyflavones inhibit PDE5, the same enzyme sildenafil blocks, and raise nitric oxide output from vessel-lining cells. Human evidence is real but weak — a 30-day open-label study in 13 middle-aged and older men with self-reported mild erectile dysfunction improved erectile function, intercourse satisfaction and total questionnaire score. There was no placebo arm, outcomes were self-reported, and the sponsor sells the ingredient. The pooled analysis found sexual-function benefit but drew its effect estimates predominantly from animal models.

Magnitude: 61.5% of completers reported improved erections after 30 days at 100 mg daily, with mean intercourse-satisfaction scores rising about 13% and penetration-frequency scores about 12.5% (Stein et al., 2018); measured potency against PDE5 is roughly three orders of magnitude weaker than a prescription inhibitor (Temkitthawon et al., 2011).

Low 🟩

Shift Toward Parasympathetic Autonomic Balance

One 12-week trial in 194 adolescent athletes found higher heart-rate-variability indices — beat-to-beat variation reflecting rest-and-digest nervous activity — plus a higher stress-resistance score and lower stress index, without changing overall autonomic balance. Pooled data also report lower resting heart rate. The signal is single-population and secondary.

Magnitude: Direction is consistently toward higher heart-rate-variability indices and lower resting heart rate at 360 mg daily over 12 weeks in trained adolescents, and the effect holds only where dosing continues; the reports state statistical significance without publishing an interpretable effect size for these endpoints (Sripanidkulchai et al., 2022).

Speculative 🟨

Cellular Longevity Signaling

Basis is mechanistic and invertebrate only: one methoxyflavone activates human SIRT1 in the test tube more potently than resveratrol, and rhizome extract extended lifespan in the roundworm Caenorhabditis elegans. No mammalian lifespan data exist.

Skin Aging Support

Basis is laboratory and reconstructed-tissue only: methoxyflavones raised collagen and hyaluronic acid and reduced oxidative damage in photoaged three-dimensional human skin models. The accompanying human work tested irritation and sensitization, not wrinkle or elasticity outcomes.

Benefit-Modifying Factors

  • Brown adipose tissue activity at baseline: The single best-documented modifier. Acute energy expenditure rose sharply in volunteers with high brown-fat activity and not at all in those with low activity, which plausibly explains why fat-loss trials in older or sedentary groups would underperform.

  • Baseline visceral fat and triglycerides: Every positive body-composition trial recruited overweight adults with a body mass index of 23–30. Lean users have far less visceral fat to lose, and the triglyceride fall was largest in those starting higher.

  • Baseline glucose: Pooled glucose benefit contrasts with a null result in metabolically healthy volunteers, suggesting the effect is confined to people with elevated fasting glucose. No change is expected in those already in an optimal range.

  • Genetic variation in intestinal CYP3A and UGT enzymes: These enzymes (UGT is uridine diphosphate glucuronosyltransferase, which attaches sugar groups to compounds for excretion) perform the first-pass clearance that limits absorption to a few percent. Fast metabolizers absorb less.

  • Sex: Body-composition trials enrolled mostly women, sexual-function trials only men, and no trial has reported sex-stratified results. Whether the metabolic effect differs by sex is untested rather than absent.

  • Pre-existing conditions: Vascular erectile dysfunction is the plausible responder phenotype given the nitric-oxide mechanism; erectile dysfunction of neurological, hormonal or psychological origin has no mechanistic reason to respond.

  • Age: Trials span adolescent athletes to volunteers in their sixties, with benefit reported at both ends. Older adults gained on functional measures at 90 mg daily, a far lower dose than the athlete protocols used.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Gastrointestinal Discomfort

The only adverse effect captured systematically in placebo-controlled trials, and the evidence that it is mild is strong. Across 12-week double-blind trials with formal adverse-event collection, blood chemistry, hematology and urinalysis, reported events were transient, evenly distributed between arms, and unrelated by investigator judgment to the test product. A 90-day rat study at up to 249 mg/kg daily produced no toxicologically relevant biochemical change, and reverse-mutation testing found no genotoxicity (DNA damage). The practical caution is dose- and timing-related rather than serious.

Magnitude: Abdominal pain in 2 of 38 participants on extract versus 1 of 38 on placebo over 12 weeks, with no clinically relevant abnormality in any laboratory parameter (Yoshino et al., 2018); adverse-reaction rates were 52% on extract versus 48% on placebo in a 2025 trial, with the difference not significant (Sung et al., 2025).

Medium 🟥 🟥

Elevated Blood Levels of Co-administered Medications

The most consequential risk, and the one users are least likely to anticipate. The extract and its two principal methoxyflavones competitively and time-dependently inhibit CYP3A, the enzyme handling most prescription drugs, at concentrations below those estimated to occur in the small intestine after a normal capsule. Separately, the extract and its pentamethoxyflavone inhibit P-glycoprotein, the pump that limits absorption of many drugs. Both actions push co-administered drug levels upward. No human interaction study has been run, so the magnitude in people is unmeasured.

Magnitude: Inhibition constant of 78.14 µg/mL against midazolam hydroxylation in human liver microsomes, with a 2.3-fold rise in midazolam exposure and 1.9-fold rise in peak concentration in rats dosed 2 hours earlier (Kashiwabuchi et al., 2022); 10 days of 5,7-dimethoxyflavone raised midazolam exposure 130% in mice (Ochiai et al., 2018).

Low 🟥

Reduced Effect of Sildenafil Taken Concurrently

Counterintuitive, since both act on the same pathway, but the pharmacokinetic direction opposes the pharmacodynamic one. In rats, co-administration cut sildenafil exposure and accelerated its elimination, so a man combining the two may get less from the drug, not more. Rodent-only evidence, single study.

Magnitude: Sildenafil area under the curve fell 60–65%, peak concentration 40–52%, and half-life 32–54%, with elimination rate rising 37–77% (Mekjaruskul & Sripanidkulchai, 2015).

Liver Histology Change at High Chronic Doses ⚠️ Conflicted

A 60-day rat study at 60–240 mg/kg daily found normal liver enzymes, kidney markers and blood counts yet morphological liver change on microscopy, and judged high chronic human dosing inadvisable. A 90-day study at comparable doses found no histopathological change. Routine blood work would miss either.

Magnitude: Morphological liver change appeared at 60–240 mg/kg daily for 60 days in rats while alanine aminotransferase, aspartate aminotransferase, urea nitrogen and creatinine all stayed within normal limits (Sudwan et al., 2006).

Speculative 🟨

Additive Blood-Pressure Lowering

No trial has found a blood-pressure change, but the extract widens vessels via nitric oxide and weak PDE5 inhibition. Combining it with nitrates or other vasodilators is an untested route to abnormally low blood pressure.

Hypersensitivity Reaction

A published case report documents anaphylaxis (a severe whole-body allergic reaction) from a black ginger supplement; consumer reports describe itching, rash or swelling. No trial recorded such an event; ginger-family cross-reactivity is the plausible mechanism.

Risk-Modifying Factors

  • CYP3A5 and ABCB1 genotype: CYP3A5 is a drug-metabolizing enzyme and ABCB1 encodes P-glycoprotein, the drug-efflux pump. Poor-function variants of either leave less reserve capacity, so enzyme inhibition by the extract has proportionally more effect on co-administered drug levels.

  • Baseline liver enzymes and liver imaging: Anyone starting with elevated alanine aminotransferase, fatty-liver findings or a history of drug-induced liver injury has less margin against the rodent histology signal, which occurred with normal enzymes.

  • Sex: No sex-stratified safety analysis exists in any trial. Body-composition trials enrolled predominantly women and reported no sex difference in adverse events, but the analyses were not powered to detect one.

  • Polypharmacy and narrow-therapeutic-index drugs: Risk scales directly with the number of CYP3A4 or P-glycoprotein substrates taken. Someone on no medication carries almost no interaction risk; someone on tacrolimus, apixaban or digoxin carries most of it.

  • Age: Older adults are simultaneously more likely to be on interacting medication, to have reduced liver reserve, and to have used the lowest studied doses. Age raises interaction exposure more than it raises intrinsic toxicity.

Key Interactions & Contraindications

  • CYP3A4-metabolized prescription drugs (simvastatin, atorvastatin, amlodipine, tacrolimus, cyclosporine, apixaban, rivaroxaban, midazolam, amiodarone): Caution; inhibition raises drug levels, risking muscle injury, bleeding or excess sedation. Mitigation is dosing separated by at least 4 hours plus monitoring of drug-specific markers.

  • P-glycoprotein substrate drugs (digoxin, dabigatran, fexofenadine): Caution; pump inhibition increases absorption and plasma levels, risking digoxin toxicity or bleeding. Where a drug level can be measured, it is rechecked 2–4 weeks after the extract starts.

  • Prescription PDE5 inhibitors (sildenafil, tadalafil, vardenafil): Caution rather than contraindication; rodent data show reduced sildenafil exposure and a blunted drug effect, while the shared vessel-widening mechanism raises a theoretical low-blood-pressure risk. The combination is untested outside medical supervision.

  • Nitrates and nitric-oxide donors (nitroglycerin, isosorbide mononitrate): Absolute contraindication by precaution; both act on the same vessel-relaxing pathway and the combination is the established route to a severe blood-pressure drop with any PDE5 inhibitor. No safety data exist for this combination.

  • Antihypertensive medication (amlodipine, lisinopril, losartan): Caution; additive vessel widening could produce dizziness or light-headedness on standing, and amlodipine is additionally a CYP3A4 substrate. Seated and standing blood pressure is checked weekly for the first month.

  • Over-the-counter medications (acetaminophen, ibuprofen, omeprazole, loratadine, dextromethorphan): Monitor; rodent work shows altered acetaminophen pharmacokinetics, and several of these are handled by CYP3A4 or CYP2E1 (another drug-metabolizing enzyme). Maximal acetaminophen dosing alongside the extract has the least safety margin.

  • Grapefruit juice and other CYP3A4-inhibiting foods: Caution; the inhibitory effects compound, amplifying any drug-level rise. Separation by 4 hours, or avoidance, is the usual precaution.

  • Nitric-oxide-boosting supplements (L-Citrulline, L-Arginine, beetroot nitrate, Panax ginseng): Monitor; additive effect on vessel widening and blood pressure, with light-headedness as the presenting symptom, and reducing one component typically resolves it.

  • Blood-pressure-lowering supplements (hibiscus, magnesium, potassium, garlic extract, omega-3 fatty acids): Monitor; additive blood-pressure lowering risks dizziness or light-headedness. Blood-pressure monitoring rather than avoidance is the usual approach, with new agents introduced at least two weeks apart.

  • Other interventions: Caution around ablative or thermal skin procedures and around any planned procedure requiring sedation, since CYP3A4 inhibition prolongs midazolam and fentanyl action. Disclosure to an anesthetist is the standard precaution.

Populations who should avoid Thai Ginseng:

  • Pregnant or breastfeeding women — no reproductive-toxicity data in humans and no trial has enrolled them
  • People with active liver disease at Child-Pugh Class B or C (moderate to severe liver impairment) — the rodent histology signal, and hepatic clearance of the methoxyflavones
  • Anyone taking a narrow-therapeutic-index CYP3A4 substrate (tacrolimus, cyclosporine, everolimus, warfarin) without prescriber supervision
  • Anyone on long-acting or as-needed nitrate therapy
  • People within 14 days of scheduled surgery or any procedure using sedation
  • Children and adolescents under 18 outside a supervised trial setting — the only pediatric data come from a single athlete study

Risk Mitigation Strategies

  • Full medication reconciliation before starting: Prevents the CYP3A4 and P-glycoprotein interactions that are this compound’s only substantial hazard. Every prescription, over-the-counter drug and supplement is listed, and anything a pharmacist identifies as a substrate of either is flagged.

  • Four-hour separation from all medications: Reduces peak intestinal enzyme inhibition, which drives most of the interaction risk. The extract goes with breakfast when other medicines fall at midday or evening.

  • Low starting dose of 90–100 mg daily for two weeks: Limits gastrointestinal discomfort and gives an early read on tolerance before moving to the 150–180 mg used in body-composition trials.

  • Dosing with a fat-containing meal: Cuts the gastric irritation reported on an empty stomach, and simultaneously improves absorption of these poorly soluble compounds. Around 10–15 g of fat is sufficient.

  • Baseline and 12-week liver panel: Addresses the rodent liver-histology signal. Alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase are measured, and use stops if any rises above twice the upper reference limit.

  • Daily intake capped at 360 mg, with no raw rhizome powder: Keeps exposure within the range any human trial has tested, and avoids the tenfold-higher doses at which rodent liver changes appeared.

  • Blood-pressure log for the first month: Detects additive blood-pressure lowering in anyone on antihypertensives or vessel-widening supplements. Seated and standing readings twice weekly, stopping if standing systolic drops more than 20 mmHg.

  • Two-week washout before surgery: Prevents prolonged sedative action from CYP3A4 inhibition and removes an unmeasured variable from surgical care.

Therapeutic Protocol

  • Standard dose: 100–180 mg daily of an ethanol or hydroalcoholic rhizome extract standardized to methoxyflavone content, taken once daily with food. This is the range every positive human trial used.

  • Metabolic approach: 150 mg once daily for 12 weeks, the protocol Maruzen Pharmaceuticals and Tokiwa Phytochemical used in the abdominal-fat trials. Aimed at visceral fat, measured by scan, in overweight adults.

  • Sexual-function approach: 100 mg daily of an extract standardized to 5% 5,7-dimethoxyflavone for 30 days, the Life Extension protocol. Aimed at erectile response and satisfaction rather than body composition.

  • Sports approach: 90–360 mg daily for 8–12 weeks, developed at Khon Kaen University’s Center for Research and Development of Herbal Health Products by Sripanidkulchai and Wattanathorn. Aimed at strength, sprint speed and oxygen uptake.

  • Best time of day: Morning with breakfast. Peak blood levels arrive 4–6 hours after dosing, so a morning dose places the peak in the afternoon training or activity window.

  • Half-life: 2–3 hours in humans for both measurable markers, pentamethoxyflavone and trimethoxyflavone. Peak concentration reaches about 71 ng/mL at a 180 mg dose.

  • Single versus split dosing: Every body-composition trial used a single daily capsule and succeeded, so splitting is unnecessary for metabolic goals. The short half-life makes twice-daily dosing arguable for continuous vascular effect, but untested.

  • Genetic considerations: CYP3A5 and ABCB1 variants alter first-pass clearance and therefore exposure. No pharmacogenetic dosing guidance exists; genotype is more useful for anticipating drug interactions than for setting dose.

  • Sex differences: No trial has compared doses between sexes or reported sex-stratified response. The same 150 mg dose produced fat loss in trials that were 79% female and in mixed-sex cohorts, so no adjustment is currently justified.

  • Age considerations: Older adults responded on functional measures at 25–90 mg daily, well below athlete doses. Dosing at the low end above 60 reflects greater medication burden and reduced liver reserve.

  • Baseline biomarkers: Response tracks baseline visceral fat and fasting glucose. Lean users with normal blood sugar have no documented metabolic endpoint left to improve, and performance effects are the most that could follow.

  • Pre-existing conditions: Overweight with elevated triglycerides is the studied responder profile for metabolic goals; vascular erectile dysfunction is the studied profile for sexual goals. Neither indication has been tested in diagnosed diabetes.

Discontinuation & Cycling

  • Intended duration: Short-to-medium term. No trial has run beyond 12 weeks, so continuous use past three months is an extrapolation rather than an evidence-based practice, and open-ended lifelong use has no support.

  • Withdrawal effects: None reported. No trial documented rebound weight gain, loss of erectile function below baseline, or any discontinuation symptom, and the short half-life makes physical dependence implausible.

  • Tapering: Not required. With a 2–3 hour half-life and no receptor adaptation demonstrated, abrupt cessation is appropriate, and it is also how every trial ended.

  • Cycling: No tolerance data exist in either direction. A pragmatic pattern is 12 weeks on and 4 weeks off, which matches trial duration and gives a window to confirm liver markers and reassess whether the effect was real.

  • Reassessment at discontinuation: The measurement that justified starting — waist, scan, questionnaire score or training output — is repeated. Benefits at this effect size are easily confused with seasonal or training-cycle variation.

Sourcing and Quality

  • Species authentication: Rhizomes of Kaempferia galanga and other galangals are visually similar and cheaper, and rhizome powders in this trade have been recalled for contamination. A supplier naming Kaempferia parviflora and stating the plant part as rhizome is the minimum identity check.

  • Standardization to methoxyflavones: The active fraction, not the raw plant, drives every trial result. The relevant label figure is a stated percentage of 5,7-dimethoxyflavone — 5% was used in the sexual-function trial — or a total methoxyflavone specification.

  • Extract, not powder: All human trials used ethanol or hydroalcoholic extracts. Ground raw rhizome delivers a small and variable fraction of the methoxyflavone dose, and cannot be assumed equivalent at the same milligram figure.

  • Chemotype variation: Two chemically distinct types of this plant circulate, differing substantially in methoxyflavone content, so certificate-of-analysis figures for the specific lot matter more than they would for a better-standardized botanical.

  • Branded extracts with trial data: SIRTMAX from Tokiwa Phytochemical, KaempMax used in the Life Extension study, and BG100 from Thailand’s national nanotechnology center are the three with published human or clinical-model work behind them.

  • Third-party testing: A certificate of analysis from an independent laboratory covering identity, methoxyflavone assay, heavy metals and microbial limits is the relevant document. Rhizome crops accumulate lead and cadmium from soil, making heavy-metal testing non-optional.

  • Reputable channels: Manufacturers holding NSF International, United States Pharmacopeia or Informed Choice certification, and compounding pharmacies that will disclose the raw-material supplier, are the practical routes to a lot-verified product in an unregulated ingredient category.

Practical Considerations

  • Time to effect: Energy expenditure rises within 60 minutes of a single dose. Sexual-function change was reported at 30 days, physical-fitness change at 8 weeks, and measurable abdominal-fat change only at 8–12 weeks. Judging it earlier than 12 weeks is premature.

  • Common pitfall — raw powder for extract: Buying ground rhizome at the milligram figures used in trials delivers a fraction of the methoxyflavone dose. This is the single most likely reason for a null personal result.

  • Common pitfall — expecting a drug-like erectile effect: Potency against PDE5 is orders of magnitude below a prescription inhibitor. The realistic expectation is a modest shift in self-rated function, not an on-demand response.

  • Common pitfall — ignoring the interaction profile: Users treat botanicals as interaction-free. This one inhibits the enzyme family handling most prescription drugs, which is the opposite of inert.

  • Regulatory status: Sold in the United States as a dietary supplement with no approved therapeutic indication and no premarket efficacy review. Japan permits it under Foods with Function Claims and Korea under health functional foods, both for body-fat reduction.

  • Cost and accessibility: Neither expensive nor hard to obtain — roughly $15–30 a month for a standardized extract, widely available online. Cost is not a barrier and does not warrant weighting in the decision.

  • Payer incentives: Competing options differ sharply in cost — generic sildenafil is pennies per dose and reimbursed, injectable weight-loss medicines cost hundreds monthly. Insurers have no incentive to fund research on an unreimbursable supplement, which is why manufacturers dominate its evidence base.

Interaction with Foundational Habits

  • Sleep: Direction is neutral with no established mechanism. The extract contains no stimulant, and one trial deliberately used it as the non-caffeinated comparator against caffeine. The heart-rate-variability findings point mildly toward parasympathetic activity rather than arousal, so evening dosing is not contraindicated; anyone noticing restlessness can simply move it to morning.

  • Nutrition: Direction is potentiating. Methoxyflavones are fat-soluble and poorly absorbed, so a meal containing 10–15 g of fat meaningfully raises exposure, while an empty stomach both lowers absorption and increases the chance of discomfort. Grapefruit juice and other enzyme-inhibiting foods compound the drug-interaction risk, and separation by 4 hours removes that overlap.

  • Exercise: Direction is potentiating and conditional. Every strength and endurance benefit was recorded in people who were training; the fat-loss trials held activity constant and still saw an effect, so it adds to training rather than substituting for it. Morning dosing puts peak blood levels in an afternoon session.

  • Stress management: Direction is indirect. Twelve weeks of supplementation raised heart-rate-variability indices and lowered a measured stress index in athletes, and rodent work shows reduced corticosterone, together suggesting mild autonomic support rather than a true adaptogenic effect on the stress axis. It does not replace sleep, breathing practice or load management.

Monitoring Protocol & Defining Success

Baseline testing matters here less because the extract is dangerous than because its documented effects are small enough to be invisible without a starting reference. Before the first capsule, the baseline set is waist circumference, a fasting panel covering glucose, insulin and triglycerides, a liver panel, and seated blood pressure with resting heart rate. For sexual-function use it extends to a validated erectile-function questionnaire and morning total and free testosterone. For a body-composition goal it extends to a dual-energy X-ray absorptiometry (DEXA, a body-composition scan) or computed tomography scan, because scales and tape measures cannot isolate the visceral compartment the trials actually moved.

The liver panel and blood pressure repeat at 4 weeks, the full panel and waist measurement at 12 weeks — the shortest interval at which any trial detected fat change — and thereafter every 6 months while use continues.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Waist circumference Men below 94 cm; women below 80 cm Cheapest proxy for the visceral compartment the trials targeted Measured at the iliac crest at the end of a normal exhale, same time of day; lags scan-measured change by weeks
Visceral fat area (computed tomography or DEXA android region) Below 100 cm² The primary endpoint in every positive body-composition trial Repeated no sooner than 12 weeks; radiation and cost argue for waist plus bioimpedance for interim tracking
Fasting glucose 75–90 mg/dL (4.2–5.0 mmol/L) The one metabolic marker with a pooled human benefit signal Drawn after a 10–12 hour fast; conventional labs flag nothing below 100 mg/dL, which hides early drift
Fasting insulin and HOMA-IR Insulin below 6 µIU/mL; HOMA-IR below 1.5 Detects improved insulin sensitivity before fasting glucose moves HOMA-IR (homeostatic model assessment of insulin resistance) is calculated from paired fasting glucose and insulin; most labs flag insulin only above 25 µIU/mL
Triglycerides Below 80 mg/dL (below 0.9 mmol/L) Fell significantly against placebo in the 12-week abdominal-fat trial 12-hour fast and no alcohol for 48 hours; the conventional cut-off of 150 mg/dL is far too permissive
ALT, AST and GGT ALT below 25 U/L (men) or 20 U/L (women); GGT below 20 U/L Rodent work found liver histology change at high chronic doses despite normal enzymes ALT (alanine aminotransferase), AST (aspartate aminotransferase) and GGT (gamma-glutamyl transferase) are liver enzymes; conventional upper limits near 40–50 U/L miss early change
Seated blood pressure and resting heart rate Below 120/80 mmHg; resting heart rate 50–65 bpm The extract widens vessels and pooled data suggest a lower resting heart rate Seated after 5 minutes’ rest, averaged over three readings; conventional practice flags a resting heart rate only outside 60–100 bpm, so the 50–65 bpm target sits inside the “normal” band; essential for anyone on antihypertensive medication
Total and free testosterone (men) Total 500–800 ng/dL; free 15–25 ng/dL Trials found no hormonal change; measuring it tests the marketing claim directly Drawn before 10 a.m.; the conventional laboratory range runs roughly 264–916 ng/dL, so a mid-range result reads as normal while sitting below the functional target; paired with SHBG (sex hormone-binding globulin, the protein binding most circulating testosterone)

Qualitative markers worth tracking alongside the laboratory work:

  • Erectile-function score: the five-item International Index of Erectile Function (IIEF-5, a validated questionnaire rating erection quality over the previous four weeks) at baseline, week 4 and week 12
  • Training output: load moved, sprint or interval times, and session volume, since the documented strength effect is small enough to be lost in ordinary week-to-week variation
  • Perceived exertion and recovery: rating of perceived exertion at a fixed workload, and next-day soreness, which is where the lactate and oxidative-stress findings would surface subjectively
  • Waistband fit: a more sensitive week-to-week signal of visceral change than body weight, which the trials largely failed to move
  • Energy and alertness through the afternoon: the window in which blood levels peak, and the endpoint the non-caffeinated energy trial was built around

Emerging Research

  • No trial currently recruiting: An August 2026 search of ClinicalTrials.gov returns four registered studies involving this plant, all completed. Nothing is recruiting, no phase 2 or 3 program exists, and registration activity sits entirely with small academic and industry proof-of-concept work rather than definitive trials.

  • Acute metabolic proof of concept: NCT06805201 randomized 10 active men to 100 mg or 200 mg of a three-ginger blend and measured resting metabolic rate and respiratory quotient over 180 minutes — a direct test of the energy-expenditure mechanism, but double-blind without a placebo arm and far too small to settle anything.

  • Head-to-head against caffeine: NCT04895800 compared a botanical blend containing this extract against green-tea caffeine and placebo in 36 active adults over 21 days, with attention, mood, time-to-exhaustion and stress biomarkers as endpoints. The multi-ingredient design prevents attributing any result to the extract alone.

  • Registered sexual-function study: NCT03389867 is the registry record for the 14-man open-label erectile-function study. Its design — no placebo, self-reported outcomes, sponsor-run — defines exactly what a confirmatory trial would need to correct, and none has been registered since.

  • Topical route: NCT04769193 tested a face cream combining this rhizome extract with safflower seed oil in 35 volunteers, measuring skin elasticity and facial volume at 6 and 12 months. Single-arm and industry-sponsored, but it extends the compound beyond oral use.

  • Evidence that could weaken the case: The one trial designed to test glucose handling found no effect at 90 or 180 mg daily for 28 days (Sripanidkulchai et al., 2019), sitting directly against the pooled fasting-glucose finding. Any adequately powered replication in healthy adults could remove that benefit entirely.

  • Independent replication is the missing study: Every positive body-composition trial was run or funded by a company selling the extract. An investigator-initiated, publicly funded 12-week replication would be the single most informative study the field could produce, and none is registered.

  • Muscle preservation in aging: Standardized extract improved protein-metabolism pathways and reduced markers of sarcopenia (age-related muscle loss) in aged mice (Kim et al., 2026). If it survives translation, this would extend the performance findings from athletes to the population that most needs them.

  • Bioavailability engineering: Nanosuspensions, self-microemulsifying systems and transdermal patches are all being developed to bypass the 1–4% oral bioavailability ceiling (Mekjaruskul & Sripanidkulchai, 2020). Success would raise both the effect size and the interaction risk simultaneously.

Conclusion

Thai ginseng is a purple-fleshed relative of ginger from mainland Southeast Asia, taken for centuries as a stamina and virility tonic and sold today as a standardized capsule. Its chemistry is unusual and its two proposed actions — widening blood vessels and shifting cells from storing fuel toward burning it — are both plausible and partly demonstrated in people.

What the human record supports is modest. Loss of abdominal and total body fat over three months is the most replicated result, and small gains in strength and endurance the next most. Lower fasting blood sugar appears in pooled data but vanished in the one study built to look for it. The sexual-function claim that made the plant famous rests on a handful of small, mostly uncontrolled studies. Side effects have been mild across every trial run so far.

Two caveats carry real weight. Almost all the positive human research was funded or conducted by companies selling the extract — Maruzen Pharmaceuticals, Tokiwa Phytochemical and Life Extension among them — and no independent group has replicated any of it. And the compound blocks the enzyme system that clears most prescription drugs, an interaction never measured in people. For someone on medication, that unmeasured interaction is the dominant consideration; for someone on none, the honest summary is a small, well-tolerated, commercially sponsored effect.

Top - Benefits - Risks - Protocol